$150M Stock Offering Closes for Immix Biopharma, Bolstering Funds After Strong NXC-201 Trial Results
IMMX has more than doubled off its 52-week low of $1.87 on elevated volume (2.9× avg).
Summary
Immix Biopharma has successfully closed its $150 million underwritten public offering, securing approximately $140.65 million in net proceeds. This significant capital raise follows the company's recent announcement of a 95% complete response rate for its NXC-201 therapy in a Phase 2 clinical trial. The offering, which saw participation from leading institutional investors, provides a substantial cash infusion to fund the continued development of its promising drug pipeline and extends the company's financial runway, especially given its previously reported increased cash burn.
At the time of this announcement, IMMX was trading at $8.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $477.7M. The 52-week trading range was $1.87 to $11.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.